Back to search results
NCT07632157

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatment
Wake Forest University Health Sciences
~196 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:Magnesium Sulfate 2gMagnesium Sulfate 4gSaline (0.9% NaCl)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ventricular rate control
Measured over Within the first 2 hours of intravenous magnesium administration

Conditions

Atrial Flutter With Rapid Ventricular Response

Explore related trials

Atrial FibrillationAtrial Flutter

NCT07632157

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Advocate Christ Medical Center Emergency Department (ACMC ED)

    Oak Lawn, Illinoisno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Marc McDowell, PharmD · PRINCIPAL_INVESTIGATOR · Advocate Christ Medical Center Emergency Department

Who to contact

Marc McDowell, PharmD
[email protected]
(708) 684-1078
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 18 years or older
Able to provide informed consent
Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
Metoprolol as rate control agent
English speaking

Exclusion

Hemodynamically unstable patients (SBP \<90, MAP \<65)
Impaired consciousness
Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
Acute myocardial infarction
Contraindications to magnesium sulfate (including myasthenia gravis)
Allergy or sensitivity to any study drugs
Previously enrolled in this trial during a different patient encounter
Withdrew from study

What this trial measures

  • Ventricular rate controlWithin the first 2 hours of intravenous magnesium administration

    Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of \< 120 beats per minute.